• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Recent Advances in the Application of Ethyl 3-(2-aminothiazol-4-yl)propanoate (CAS: 182939-65-7) in Chemical Biology and Pharmaceutical Research

Ethyl 3-(2-aminothiazol-4-yl)propanoate (CAS: 182939-65-7) has emerged as a key intermediate in the synthesis of biologically active compounds, particularly in the development of novel antimicrobial and anticancer agents. Recent studies have highlighted its versatility as a building block for thiazole-containing pharmacophores, which are known for their broad spectrum of biological activities. This research brief synthesizes the latest findings on this compound's applications, synthetic methodologies, and structure-activity relationships.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in developing potent EGFR inhibitors. Researchers modified the ester moiety of Ethyl 3-(2-aminothiazol-4-yl)propanoate to create a series of 4-anilinoquinazoline derivatives, showing improved kinase inhibition profiles compared to first-generation inhibitors. The optimal compound in this series exhibited IC50 values below 10 nM against mutant EGFR isoforms, suggesting promising therapeutic potential for non-small cell lung cancer treatment.

In antimicrobial research, a team from the University of Tokyo recently reported (Antimicrobial Agents and Chemotherapy, 2024) novel β-lactamase inhibitors derived from Ethyl 3-(2-aminothiazol-4-yl)propanoate. The study revealed that structural modifications at the 2-amino position significantly enhanced inhibitory activity against class A and class C β-lactamases, with lead compounds restoring meropenem susceptibility in carbapenem-resistant Enterobacteriaceae at concentrations as low as 2 μg/mL.

Significant progress has also been made in the synthetic chemistry of this compound. A 2024 Nature Protocols article detailed an improved synthetic route for Ethyl 3-(2-aminothiazol-4-yl)propanoate that achieves 85% yield through a one-pot, three-component reaction involving ethyl acrylate, thiourea, and α-haloketones. This methodology offers advantages in atom economy and scalability compared to traditional approaches, facilitating its broader application in drug discovery programs.

Ongoing research is exploring the compound's potential in targeted protein degradation. Preliminary results from a 2024 ACS Chemical Biology study indicate that derivatives of Ethyl 3-(2-aminothiazol-4-yl)propanoate can serve as effective E3 ligase-recruiting moieties in PROTAC design, with several analogs demonstrating selective degradation of BRD4 at nanomolar concentrations. These findings open new avenues for developing thiazole-based degraders for challenging therapeutic targets.

From a drug metabolism perspective, recent pharmacokinetic studies (Xenobiotica, 2023) have characterized the metabolic fate of Ethyl 3-(2-aminothiazol-4-yl)propanoate derivatives. The 2-aminothiazole core shows remarkable metabolic stability, while the ester group serves as a tunable site for prodrug development. These properties make it particularly valuable for optimizing the ADME profiles of candidate molecules in preclinical development.

Looking forward, the unique structural features of Ethyl 3-(2-aminothiazol-4-yl)propanoate continue to inspire innovative applications across multiple therapeutic areas. Its combination of synthetic accessibility, structural diversity, and proven biological relevance ensures its ongoing importance in medicinal chemistry research. Future directions likely include exploration in RNA-targeted therapeutics and covalent inhibitor design, building on the compound's established versatility in small molecule drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)